内容紹介
Efficacy of WT1 Peptide-/MUC-1 Peptide-Pulsed Dendritic Cell Therapy in 313 Patients with a Wide Range of Cancers
Summary
We assessed the efficacy of Wilms' tumor protein-1(WT1)peptide- and/or mucin 1(MUC-1)peptide-pulsed dendritic cell(DC)therapy for a wide range of advanced cancers. This retrospective study included 313 patients with advanced cancer who were vaccinated ≥5 times in our clinic between May 2009 and October 2013. The clinical response was evaluated. This treatment was approved by the ethics panel of our institution. A total of 313 patients were injected an average of 6.0 times with DCs(2.4×10/ 7 cells/injection). Overall, 292 of the 313(93%)patients obtained clinical benefit according to the Response Evaluation Criteria in Solid Tumors(RECIST), version 1.1. The median survival time(MST)from diagnosis and from first being admitted to this institution was 28.4 months and 13.2 months, respectively. Complete response(CR)was achieved in 21 patients(7.2%). Partial response(PR)was achieved in 69 patients(24%). Stable disease(SD)was observed in 107 patients(37%), and progressive disease(PD)was observed in 95 patients(33%). The response rate(RR)and disease control rate(DCR)for each type of cancer were as follows: colorectal cancer(56 patients), 25% and 45%, respectively; lung cancer(39 patients), 31% and 82%, respectively; pancreatic cancer(36 patients), 22% and 64%, respectively; gastric cancer(34 patients), 32% and 74%; breast cancer(20 patients), 15% and 75%, respectively; ovarian cancer(16 patients), 19% and 50%, respectively; esophageal cancer(15 patients), 20% and 73%, respectively; and others(76 patients), 38% and 67%. These results demonstrated the potential clinical effectiveness of DC-based immunotherapy.
要旨
目的: 多種の進行癌に対するWT1ペプチドとMUC-1ペプチドをパルスした樹状細胞療法の成績を明らかにする。対象および方法: この研究は後ろ向きに調査し,新横浜かとうクリニックにおいて2009年5月～2013年10月までに樹状細胞がんワクチンを5回以上接種した計313例を対象とした。臨床効果を解析した。当治療は施設の倫理委員会の承認を得ている。結果313例は,投与回数平均6.0回,平均2.4×10/ 7個/回の樹状細胞を接種した。313例中292例がRECIST v1.1で臨床評価できた。診断時からの全生存期間は中央値28.4か月,当院初診からの生存期間は13か月(1年生存率51.4%,2年生存率36.4%),CR 7.2%(21例),PR 24%(69例),SD 37%(107例),PD 33%(95例)と治療効果があり,大腸癌は56例,response rate(RR)・disease control rate(DCR)は,25%・45%,肺癌39例,31%・82%,膵癌36例,22%・64%,胃癌34例,32%・74%,乳癌20例,15%・75%,卵巣癌16例,19%・50%,食道癌15例,20%・73%,その他の癌76例,38%・67%の癌腫別に違いがあり,この結果は樹状細胞を使った免疫療法が一定の臨床効果があることを示している。
目次
Summary
We assessed the efficacy of Wilms' tumor protein-1(WT1)peptide- and/or mucin 1(MUC-1)peptide-pulsed dendritic cell(DC)therapy for a wide range of advanced cancers. This retrospective study included 313 patients with advanced cancer who were vaccinated ≥5 times in our clinic between May 2009 and October 2013. The clinical response was evaluated. This treatment was approved by the ethics panel of our institution. A total of 313 patients were injected an average of 6.0 times with DCs(2.4×10/ 7 cells/injection). Overall, 292 of the 313(93%)patients obtained clinical benefit according to the Response Evaluation Criteria in Solid Tumors(RECIST), version 1.1. The median survival time(MST)from diagnosis and from first being admitted to this institution was 28.4 months and 13.2 months, respectively. Complete response(CR)was achieved in 21 patients(7.2%). Partial response(PR)was achieved in 69 patients(24%). Stable disease(SD)was observed in 107 patients(37%), and progressive disease(PD)was observed in 95 patients(33%). The response rate(RR)and disease control rate(DCR)for each type of cancer were as follows: colorectal cancer(56 patients), 25% and 45%, respectively; lung cancer(39 patients), 31% and 82%, respectively; pancreatic cancer(36 patients), 22% and 64%, respectively; gastric cancer(34 patients), 32% and 74%; breast cancer(20 patients), 15% and 75%, respectively; ovarian cancer(16 patients), 19% and 50%, respectively; esophageal cancer(15 patients), 20% and 73%, respectively; and others(76 patients), 38% and 67%. These results demonstrated the potential clinical effectiveness of DC-based immunotherapy.
要旨
目的: 多種の進行癌に対するWT1ペプチドとMUC-1ペプチドをパルスした樹状細胞療法の成績を明らかにする。対象および方法: この研究は後ろ向きに調査し,新横浜かとうクリニックにおいて2009年5月～2013年10月までに樹状細胞がんワクチンを5回以上接種した計313例を対象とした。臨床効果を解析した。当治療は施設の倫理委員会の承認を得ている。結果313例は,投与回数平均6.0回,平均2.4×10/ 7個/回の樹状細胞を接種した。313例中292例がRECIST v1.1で臨床評価できた。診断時からの全生存期間は中央値28.4か月,当院初診からの生存期間は13か月(1年生存率51.4%,2年生存率36.4%),CR 7.2%(21例),PR 24%(69例),SD 37%(107例),PD 33%(95例)と治療効果があり,大腸癌は56例,response rate(RR)・disease control rate(DCR)は,25%・45%,肺癌39例,31%・82%,膵癌36例,22%・64%,胃癌34例,32%・74%,乳癌20例,15%・75%,卵巣癌16例,19%・50%,食道癌15例,20%・73%,その他の癌76例,38%・67%の癌腫別に違いがあり,この結果は樹状細胞を使った免疫療法が一定の臨床効果があることを示している。